Literature DB >> 25029118

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Kyuichi Kadota1, Yi-Chen Yeh, Sandra P D'Angelo, Andre L Moreira, Deborah Kuk, Camelia S Sima, Gregory J Riely, Maria E Arcila, Mark G Kris, Valerie W Rusch, Prasad S Adusumilli, William D Travis.   

Abstract

Multiple reports indicate that epidermal growth factor receptor (EGFR) mutations are associated with lepidic-pattern lung adenocarcinoma and that KRAS mutations are associated with invasive mucinous adenocarcinoma. We sought to investigate the association between EGFR and KRAS mutations and specific morphologic characteristics, such as predominant histologic subtype and mucinous features. Clinical data for 864 patients with resected lung adenocarcinoma that underwent molecular testing for EGFR and KRAS mutations were collected. Histologic subtyping was performed according to the IASLC/ATS/ERS lung adenocarcinoma classification, with attention given to signet-ring cell feature and extracellular mucin. EGFR mutations were detected using a polymerase chain reaction-based sizing assay, KRAS mutations were detected using Sanger sequencing, and ALK expression was detected using immunohistochemistry. Invasive mucinous adenocarcinoma was associated with KRAS mutation (P<0.001). Among invasive mucinous adenocarcinomas with KRAS mutation, a pure mucinous pattern was more common than a mixed mucinous/nonmucinous pattern (P=0.002). Invasive mucinous adenocarcinoma was associated with KRAS transition mutations (G→A) but not transversion mutations (G→T or G→C) compared with nonmucinous tumors (P=0.009). The lepidic-predominant group was associated with EGFR mutation compared with nonlepidic-predominant tumors (P=0.011). Extracellular mucin was associated with KRAS mutation (P<0.001), whereas signet-ring cell feature was not associated with EGFR or KRAS mutation (P=0.517). ALK expression was associated with signet-ring cell feature (P=0.001) but not with extracellular mucin (P=0.089). Our study shows that histologic patterns of mucin in lung adenocarcinoma-including invasive mucinous adenocarcinoma and extracellular mucin-are associated with KRAS mutation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25029118      PMCID: PMC4666292          DOI: 10.1097/PAS.0000000000000246

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  56 in total

1.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

2.  Clinicopathological features of lung adenocarcinoma with KRAS mutations.

Authors:  Seiichi Kakegawa; Kimihiro Shimizu; Masayuki Sugano; Yohei Miyamae; Kyoichi Kaira; Takuya Araki; Tetsuhiro Nakano; Mitsuhiro Kamiyoshihara; Osamu Kawashima; Izumi Takeyoshi
Journal:  Cancer       Date:  2011-03-08       Impact factor: 6.860

3.  Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.

Authors:  Hélène Blons; Jean-François Côté; Delphine Le Corre; Marc Riquet; Elisabeth Fabre-Guilevin; Pierre Laurent-Puig; Claire Danel
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

4.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Authors:  Maria Paola Martelli; Gabriella Sozzi; Luis Hernandez; Valentina Pettirossi; Alba Navarro; Davide Conte; Patrizia Gasparini; Federica Perrone; Piergiorgio Modena; Ugo Pastorino; Antonino Carbone; Alessandra Fabbri; Angelo Sidoni; Shigeo Nakamura; Marcello Gambacorta; Pedro Luis Fernández; Jose Ramirez; John K C Chan; Walter Franco Grigioni; Elias Campo; Stefano A Pileri; Brunangelo Falini
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

5.  Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Authors:  Karin E Finberg; Lecia V Sequist; Victoria A Joshi; Alona Muzikansky; Julie M Miller; Moonjoo Han; Javad Beheshti; Lucian R Chirieac; Eugene J Mark; A John Iafrate
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

6.  Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias.

Authors:  Koei Ikeda; Hiroaki Nomori; Yasuomi Ohba; Hidekatsu Shibata; Takeshi Mori; Yumi Honda; Ken-Ichi Iyama; Toshiaki Kobayashi
Journal:  J Thorac Oncol       Date:  2008-05       Impact factor: 15.609

7.  Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Authors:  Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn R Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

Review 8.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Cancer Sci       Date:  2007-09-20       Impact factor: 6.716

9.  Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Authors:  Jenifer L Marks; Stephen Broderick; Qin Zhou; Dhananjay Chitale; Allan R Li; Maureen F Zakowski; Mark G Kris; Valerie W Rusch; Christopher G Azzoli; Venkatraman E Seshan; Marc Ladanyi; William Pao
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

10.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

View more
  53 in total

1.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

Authors:  Christine Khoo; Toni-Maree Rogers; Andrew Fellowes; Anthony Bell; Stephen Fox
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

Review 4.  [Grading of lung cancer].

Authors:  R M Bohle; P A Schnabel
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

5.  Rebuttal from Professor Sanja Dacic.

Authors:  Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-04

6.  Pros: the present classification of mucinous adenocarcinomas of the lung.

Authors:  Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-04

7.  Cons: the confusing mucinous adenocarcinoma classification.

Authors:  Helmut H Popper
Journal:  Transl Lung Cancer Res       Date:  2017-04

8.  Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer.

Authors:  Takamichi Igarashi; Kimihiro Shimizu; Kengo Usui; Takehiko Yokobori; Yoichi Ohtaki; Seshiru Nakazawa; Kai Obayashi; Toshiki Yajima; Sumihito Nobusawa; Takahiro Ohkawa; Ryuji Katoh; Yoko Motegi; Hiroomi Ogawa; Norifumi Harimoto; Tatsuo Ichihara; Yasumasa Mitani; Hideaki Yokoo; Akira Mogi; Ken Shirabe
Journal:  Int J Clin Oncol       Date:  2019-11-26       Impact factor: 3.402

9.  Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases.

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Frances Hughes; Tina Mullis; Nicola Trim; Philippe Taniere
Journal:  Pathol Oncol Res       Date:  2018-08-09       Impact factor: 3.201

10.  Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.

Authors:  Yang Qu; Dan Zhao; Jing Mu; Nanying Che; Chen Zhang; Zichen Liu; Dan Su; Lijuan Zhou; Haiqing Zhang; Lixin Wei
Journal:  Tumour Biol       Date:  2015-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.